Jump to section
To solve systemic problems of the healthcare system, redefining how the business of healthcare performs.
Few candidates hear
back within 2 weeks
45% female employees
31% employee growth in 12 months
The high cost of prescription drugs in the US is a significant point of contention within the healthcare sector, particularly as prices continue rising. Despite policy proposals to combat this, very few changes have been made to tackle the problem of information asymmetry, where decisions are made by healthcare professionals without concrete knowledge of drug costs. Kalderos is a cloud platform that aims to bridge this gap to create a more transparent system for medical professionals and patients alike.
Using a machine learning platform, Kalderos identifies and resolves non-compliance in drug processes and costs to provide widely accessible data so that informed decisions can be made. The platform has worked with government bodies to demonstrate how it facilitates transparency in the sector to create a more efficient, honest process that is cost-effective for hospitals and patients.
Recent developments include a new Dispute Centre that provides drug discount management teams with sophisticated and detailed insights into the resolution process for disputes. This enables increased visibility that aims to ease workflows in order to allow users to maintain focus on treating patients. Kalderos is continually investing in its platform in order to create solutions like this for maximum transparency.
Kirsty
Company Specialist at Welcome to the Jungle
Sep 2022
$15m
LATE VC
Jun 2020
$28m
SERIES B
This company has top investors
Jeremy Docken
(Chief Strategy Officer)Previously a Senior Treasury Analyst of Securitizations at Harley Davidson Financial Services. Also worked as a Director of Pharmaceutical Advisory Practice at KPMG and as Director of Data Niche at IMS Health. Was the CEO of Kalderos until May 2021.